We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Digital Diagnostic Platform Uses Electronic Technology for Rapid Disease Detection

By LabMedica International staff writers
Posted on 02 Jun 2025

Traditional diagnostic methods often fall short in providing rapid, accurate detection of infectious diseases, leading to delays in treatment and increased transmission. More...

Now, a groundbreaking digital diagnostics platform aims to revolutionize point-of-care testing with real-time, high-sensitivity results.

The platform, developed by IdentifySensors Biologics (Shaker Heights, OH, USA), utilizes advanced graphene-based sensors integrated into a compact, reusable Bluetooth-enabled device. This technology allows for the detection of multiple pathogens from a single saliva sample without the need for enzymatic amplification or reagents, streamlining the diagnostic process. The system comprises a handheld reader and disposable test cartridges capable of identifying up to three pathogens simultaneously. By targeting conserved genomic regions, the platform ensures high specificity and sensitivity, surpassing traditional PCR tests in detecting viral concentrations as low as 200 copies per milliliter.

Preliminary clinical trials have demonstrated approximately 98% accuracy in rapid result delivery from verified COVID-19 samples. Beyond COVID-19, the platform is being developed to detect a broad spectrum of pathogens, including RSV, influenza, norovirus, rotavirus, adenovirus, HIV, hepatitis, chlamydia, gonorrhea, herpes, MRSA, Lyme disease, and tropical diseases like Zika and dengue. Its versatility and rapid turnaround make it a promising tool for both clinical settings and at-home testing, facilitating timely medical interventions and reducing disease spread. IdentifySensors has initiated the FDA review process by submitting a pre-EUA for emergency use authorization of a rapid Ebola test on the company's new Check4 platform.

"This is the new internet of things for diagnostics," said IdentifySensors CEO Greg Hummer. "Current molecular tests are old, slow, expensive and require skilled labor. Our rapid detection platform solves that through electronic circuits that connect instantly to cloud-based algorithms and healthcare software systems."

Related Links:
IdentifySensors Biologics


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.